Suppr超能文献

生存素表达与肝细胞癌复发及预后的关系

Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.

作者信息

Ye Chao-Ping, Qiu Cheng-Zhi, Huang Zhong-Xin, Su Qi-Chen, Zhuang Wei, Wu Rui-Lan, Li Xin-Feng

机构信息

Department of Hepatobiliary Surgery, Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.

出版信息

World J Gastroenterol. 2007 Dec 14;13(46):6264-8. doi: 10.3748/wjg.v13.i46.6264.

Abstract

AIM

To study the expression of the inhibitor of apoptosis protein survivin in hepatocellular carcinoma (HCC), and its correlation with clinicopathological factors, cell proliferation, recurrence and prognosis after hepatectomy.

METHODS

Immunohistochemical staining of survivin and Ki-67 was performed by the standard streptavidin-peroxidase technique on paraffin sections of 55 cases of HCC.

RESULTS

The positive rate of survivin in HCC was 52.7% (29/55). Significant correlation was found between survivin expression with portal vein thrombi and intrahepatic matastasistic nodes (P < 0.05). The recurrent rate in survivin-positive HCC was significantly higher than that in survivin-negative HCC after hepatectomy, the 1- and 3-year survival rate in patients with survivin-positive tumors was significantly lower than that in patients with survivin-negative tumors (58.62 and 10.34% vs 76.92 and 30.77%, P < 0.05, log-rank test). The proliferation index (Ki-67) in survivin-positive HCC (33.83% +/- 18.90%) was significantly higher than that in survivin-negative HCC (19.60% +/- 19.35%) (P < 0.05).

CONCLUSION

Survivin may play an important role in progression of HCC by promoting cell proliferation, and may be positively correlated with high risk of disease recurrence and poor prognosis in HCC. Its expression may serve as a prognostic factor for patients with HCC after hepatectomy.

摘要

目的

研究凋亡抑制蛋白生存素在肝细胞癌(HCC)中的表达及其与临床病理因素、细胞增殖、肝切除术后复发及预后的相关性。

方法

采用标准链霉亲和素-过氧化物酶技术对55例HCC石蜡切片进行生存素和Ki-67免疫组化染色。

结果

HCC中生存素阳性率为52.7%(29/55)。生存素表达与门静脉癌栓及肝内转移淋巴结之间存在显著相关性(P<0.05)。肝切除术后生存素阳性HCC的复发率显著高于生存素阴性HCC,生存素阳性肿瘤患者的1年和3年生存率显著低于生存素阴性肿瘤患者(58.62%和10.34%对76.92%和30.77%,P<0.05,对数秩检验)。生存素阳性HCC的增殖指数(Ki-67)(33.83%±18.90%)显著高于生存素阴性HCC(19.60%±19.35%)(P<0.05)。

结论

生存素可能通过促进细胞增殖在HCC进展中起重要作用,且可能与HCC疾病复发高风险及预后不良呈正相关。其表达可作为肝切除术后HCC患者的预后因素。

相似文献

1
Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.
World J Gastroenterol. 2007 Dec 14;13(46):6264-8. doi: 10.3748/wjg.v13.i46.6264.
2
Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.
J Cancer Res Clin Oncol. 2006 Sep;132(9):547-55. doi: 10.1007/s00432-006-0097-5. Epub 2006 Jun 9.
5
LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
J Cancer Res Clin Oncol. 2010 Feb;136(2):275-81. doi: 10.1007/s00432-009-0659-4. Epub 2009 Aug 19.
10
Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.
World J Gastroenterol. 2005 Jul 7;11(25):3855-9. doi: 10.3748/wjg.v11.i25.3855.

引用本文的文献

1
Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
Int J Mol Sci. 2023 Dec 22;25(1):216. doi: 10.3390/ijms25010216.
2
Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma.
Int J Mol Sci. 2018 Nov 29;19(12):3798. doi: 10.3390/ijms19123798.
4
From big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma.
PeerJ. 2017 Mar 14;5:e3089. doi: 10.7717/peerj.3089. eCollection 2017.
5
Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β.
Cell Cycle. 2016 Nov;15(21):2875-2881. doi: 10.1080/15384101.2016.1231286. Epub 2016 Oct 7.
6
Survivin as a preferential target for cancer therapy.
Int J Mol Sci. 2014 Feb 13;15(2):2494-516. doi: 10.3390/ijms15022494.
7
Meta-analysis: prognostic value of survivin in patients with hepatocellular carcinoma.
PLoS One. 2013 Dec 26;8(12):e83350. doi: 10.1371/journal.pone.0083350. eCollection 2013.
8
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.
Cancers (Basel). 2012 Apr 5;4(2):354-78. doi: 10.3390/cancers4020354.

本文引用的文献

2
Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
Clin Chem. 2006 Sep;52(9):1693-700. doi: 10.1373/clinchem.2006.071613. Epub 2006 Jul 27.
3
Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy.
Mol Cancer Ther. 2006 Mar;5(3):693-703. doi: 10.1158/1535-7163.MCT-05-0423.
4
Survivin modulates microtubule dynamics and nucleation throughout the cell cycle.
Mol Biol Cell. 2006 Mar;17(3):1483-93. doi: 10.1091/mbc.e05-08-0723. Epub 2006 Jan 11.
6
7
A survivin gene signature predicts aggressive tumor behavior.
Cancer Res. 2005 May 1;65(9):3531-4. doi: 10.1158/0008-5472.CAN-04-4284.
8
Hepatocellular carcinoma: the need for progress.
J Clin Oncol. 2005 May 1;23(13):2892-9. doi: 10.1200/JCO.2005.03.196.
9
Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells.
World J Gastroenterol. 2005 Jan 14;11(2):193-9. doi: 10.3748/wjg.v11.i2.193.
10
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
Br J Cancer. 2005 Jan 17;92(1):120-4. doi: 10.1038/sj.bjc.6602314.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验